O-295 Dual trigger does not improve reproductive outcomes in advanced maternal age women

Abstract Study question Could dual trigger increase oocyte yield and maturation rate in women of advanced maternal age (≥ 40) undergoing IVF? Summary answer Dual does not result higher or rates compared to hCG monotrigger What is known already Advanced related poor ovarian response (POR) remains a major therapeutic challenge routine IVF practice, because the association with low live birth high cancellation rates. used at end controlled hyperstimulation as surrogate LH surge induce final maturation. Recently, co-administration GnRH agonist for (dual trigger) has been suggested improve outcome (by improving quantity quality) normal responders, while evidence responders controversial. design, size, duration This retrospective cohort study including patients attending private clinic from 1st January 2018 until June 2022. Participants/materials, setting, methods All who underwent IVF/ICSI antagonist protocol our center were included. Patients may have undergone triggering either 250mcg rhCG 0.2 mg agonist. Mature oocytes inseminated using ICSI. Main results role chance In total, 2242 included, 454 (20.2%) group 1788 (79.8%) group. There was no significant difference female [41.3 (1.12) vs 41.3 (1.19), p value 0.94]. Total stimulation units also comparable between groups. The number MII did differ significantly [5.8 (4.1) 6.3 (4.7) 4.7 (3.3) 4.9 (3.4), = 0.15 0.49, respectively]. Maturation similar 81.7% (22.4) 79.8% (23.5), 0.15, well fertilization (defined fertilized divided by total cumulus-oocyte complexes recruited) [57% (29.7) 58.8% (29.4), value=0.2]. Embryo utilization embryos transferred cryopreserved fertilized) two arms: 69.7% (34.2) 70% (33.9), =0.22. Multivariate Poisson regression analysis adjusting relevant confounders (AMH, units) showed that type strategy rhCG) associated (coefficient 0.2, value=0.24) -1.8, 0.12). Limitations, reasons caution main limitation design study, an inherent risk bias. Wider implications findings To best knowledge, this largest evaluating women. Our data demonstrate cannot prognosis should be panacea all patients. Trial registration NA